The impact of acute urinary morbidity on late urinary function after permanent prostate brachytherapy

Brachytherapy

Volumn 6, Issue 4, 2007, Pages 258-266

  Bittner, Nathan ^a   Merrick, Gregory S ^b   Wallner, Kent E ^a,c   Lief, Jonathan H ^b   Butler, Wayne M ^b   Galbreath, Robert W ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b WHEELING JESUIT UNIVERSITY   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Brachytherapy; Dysuria; Prostate; Urinary morbidity

Indexed keywords

ANTIANDROGEN; GONADORELIN;

AGED; ARTICLE; BRACHYTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DYSURIA; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROSTATE CANCER; SCORING SYSTEM; SYMPTOM; TRANSURETHRAL RESECTION; URETHRA STRICTURE; URINARY DYSFUNCTION; URINE CATHETER;

AGED; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; DYSURIA; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSTATE; PROSTATIC NEOPLASMS; RISK FACTORS; TIME FACTORS;

EID: 35649027266     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2007.08.008     Document Type: Article

References (21)

1. Stone N., Stock R., and Unger P. Intermediate term biochemical-free progression and local control following 125-I brachytherapy for prostate cancer. J Urol 173 (2005) 803-807
2. Zelefsky M., Wallner K., Ling C., et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostate cancer. J Clin Oncol 17 (1999) 517-522
3. Davis J., Kuban D., Lynch D., et al. Quality-of-life after treatment for localized prostate cancer: Differences based on treatment modality. J Urol 166 (2001) 947-952
4. Merrick G.S., Butler W.M., Lief J., et al. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 47 (2000) 121-128
5. Merrick G., and Butler W. Modified uniform seed loading for prostate brachytherapy: Rationale, design, and evaluation. Tech Urol 6 (2000) 78-84
6. Wallner K., Roy J., and Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 32 (1995) 465-471
7. Allen Z.A., Merrick G.S., Butler W.M., et al. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity. Int J Radiat Oncol Biol Phys 62 (2005) 981-987
8. Wallner K., Merrick G., True L., et al. I-125 versus Pd-103 for low-risk prostate cancer: Morbidity outcomes for a prospective randomized multicenter trial. Cancer J 8 (2002) 67-73
9. Niehaus A., Merrick G.S., Butler W.M., et al. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys 64 (2006) 136-143
10. Beekman M., Merrick G.S., Butler W.M., et al. Selecting patients with pretreatment postvoid residual urine volume less than 100 mL may favorable influence brachytherapy-related urinary morbidity. Urology 66 (2005) 1266-1270
11. Merrick G.S., Butler W.M., Wallner K.E., et al. Extracapsular radiation dose distribution following permanent prostate brachytherapy. Am J Clin Oncol 26 (2003) E178-E189
12. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys 22 (1995) 209-234
13. Merrick G.S., Butler W.M., Dorsey A.T., et al. Seed fixity in the prostate/periprostatic region following brachytherapy. Int J Radiat Oncol Biol Phys 46 (2000) 215-220
14. Merrick G.S., Butler W.M., Wallner K.E., et al. Dysuria after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 55 (2003) 979-985
15. Butler W.M., Merrick G.S., Dorsey A.T., et al. Comparison of dose length, area, and volume histograms as quantifiers of urethral dose in prostate brachytherapy. Int J Radiat Oncol Biol Phys 48 (2000) 1575-1582
16. Herstein A., Wallner K.E., Merrick G.S., et al. I-125 versus Pd-103 for low-risk prostate cancer: Long-term morbidity outcomes from a prospective randomized multicenter controlled trial. Cancer J 11 (2005) 385-389
17. Merrick G., Butler W., Wallner K., et al. Long-term urinary quality of life following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 56 (2003) 454-461
18. Wallner K., Merrick G., True L., et al. 125I versus 103Pd for low-risk prostate cancer: Preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys 57 (2003) 1297-1303
19. Stock N., and Stone R. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy. Brachytherapy 2 (2003) 32-39
20. Kollmeier M., Stock R., Cesaretti J., et al. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy. J Urol 173 (2005) 808-812
21. Merrick G., Butler W., Wallner K., et al. Effect of transurethral resection on urinary quality of life after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 58 (2004) 81-88